Novo Nordisk just rebranded to Novo. The company announced sweeping corporate changes as it battles Eli Lilly for obesity market share. This is what passes for strategy when your competitor is eating your lunch.
They called it the beginning of a new chapter. That's what companies say when the current chapter involves getting destroyed. Eli Lilly owns this space. Everyone knows it. Novo knows it. The board knows it. But sure, shorten the name. That'll fix the revenue projections.
The Danish drugmaker thinks dropping Nordisk makes them sound modern. Fresh. Nimble. Here's what actually happened: a dozen consultants billed two million dollars to suggest removing a word. Then another dozen billed three million to execute the removal. Somewhere in Copenhagen, a designer spent four months kerning a logo that looks identical to the old one.
Retail traders will see this news and think it means something. They'll check the chart. They'll draw lines connecting random price points. They'll convince themselves the rebrand signals a turnaround. They'll buy calls expiring Friday. By Monday they'll be back on Reddit explaining how market makers personally targeted their position.
Novo faces stiff competition. That's the phrase journalists use when one company is getting obliterated but they need to sound diplomatic. Stiff competition. Like calling the Titanic's iceberg encounter a navigation challenge.
The obesity drug market is massive. Demand is insane. Patients are desperate. Doctors are prescribing everything. And Novo's response to losing ground is cosmetic surgery on their corporate identity. They didn't unveil a better drug. They didn't announce a price cut. They didn't solve supply chain issues. They shortened their name and called it a new chapter.
Eli Lilly is counting the money while Novo counts the letters they removed from their logo.
Photo by on Unsplash
Leave a Comment